<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Daxor Corporation — News on 6ix</title>
<link>https://6ix.com/company/daxor-corporation</link>
<description>Latest news and press releases for Daxor Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/daxor-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835607478dffbe2df0ee042.webp</url>
<title>Daxor Corporation</title>
<link>https://6ix.com/company/daxor-corporation</link>
</image>
<item>
<title>Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-leverages-medaxiom-cv-transforum-spring26-to-accelerate-commercial-adoption-of-blood-volume-analysis</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-leverages-medaxiom-cv-transforum-spring26-to-accelerate-commercial-adoption-of-blood-volume-analysis</guid>
<pubDate>Tue, 28 Apr 2026 12:00:00 GMT</pubDate>
<description>Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA™) technology at the MedAxiom CV Transforum Spring’26 Conference. The event, being held at the Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, FL, from April 30 – May 2, 2026, is a premier venue for cardiovascular thought leaders and industry innovators to drive the future of cardiac care</description>
</item>
<item>
<title>Dynamic announces April 2026 cash distributions for Dynamic Active ETFs and ETF Series</title>
<link>https://6ix.com/company/daxor-corporation/news/dynamic-announces-april-2026-cash-distributions-for-dynamic-active-etfs-and-etf-series-17</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/dynamic-announces-april-2026-cash-distributions-for-dynamic-active-etfs-and-etf-series-17</guid>
<pubDate>Mon, 20 Apr 2026 13:00:00 GMT</pubDate>
<description>Dynamic today announced the April 2026 cash distributions for the Dynamic Active ETFs and ETF series units of certain Dynamic funds (ETF Series) listed on the TSX, which pay on a monthly basis. Unitholders of record on April 27, 2026, will receive cash distributions for the respective Dynamic Active ETFs and ETF Series payable on April 30, 2026. The details of the cash distribution amounts per unit are as follows:</description>
</item>
<item>
<title>Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-expands-customer-footprint-with-new-bva-program-at-high-volume-ohio-cardiology-center</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-expands-customer-footprint-with-new-bva-program-at-high-volume-ohio-cardiology-center</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Oak Ridge, TN, April 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its</description>
</item>
<item>
<title>Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026</title>
<link>https://6ix.com/company/daxor-corporation/news/daxors-blood-volume-analysis-metric-validated-as-uniquely-accurate-versus-capillary-leak-indexes-in-new-clinical-data-presented-at-sccm-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxors-blood-volume-analysis-metric-validated-as-uniquely-accurate-versus-capillary-leak-indexes-in-new-clinical-data-presented-at-sccm-2026-1</guid>
<pubDate>Thu, 26 Mar 2026 12:00:00 GMT</pubDate>
<description>OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress. The study, titled, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control," was featured during the Resear</description>
</item>
<item>
<title>Dynamic announces March 2026 cash distributions for Dynamic Active ETFs and ETF Series</title>
<link>https://6ix.com/company/daxor-corporation/news/dynamic-announces-march-2026-cash-distributions-for-dynamic-active-etfs-and-etf-series-19</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/dynamic-announces-march-2026-cash-distributions-for-dynamic-active-etfs-and-etf-series-19</guid>
<pubDate>Thu, 19 Mar 2026 13:00:00 GMT</pubDate>
<description>Dynamic today announced the March 2026 cash distributions for the Dynamic Active ETFs and ETF series units of certain Dynamic funds (ETF Series) listed on the TSX, which pay on a monthly or quarterly basis. Unitholders of record on March 26, 2026, will receive cash distributions for the respective Dynamic Active ETFs and ETF Series payable on March 31, 2026. The details of the cash distribution amounts per unit are as follows:</description>
</item>
<item>
<title>Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-corporation-to-showcase-next-generation-portable-blood-volume-analyzer-at-acc26-highlighting-clinical-outcomes-and-reduced-readmissions</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-corporation-to-showcase-next-generation-portable-blood-volume-analyzer-at-acc26-highlighting-clinical-outcomes-and-reduced-readmissions</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces</description>
</item>
<item>
<title>Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-to-debut-new-rapid-portable-blood-volume-analyzer-at-sccm-2026-critical-care-congress</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-to-debut-new-rapid-portable-blood-volume-analyzer-at-sccm-2026-critical-care-congress</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor</description>
</item>
<item>
<title>Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-corporation-to-participate-in-the-iaccess-virtual-alpha-best-ideas-spring-investment-conference-2026</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-corporation-to-participate-in-the-iaccess-virtual-alpha-best-ideas-spring-investment-conference-2026</guid>
<pubDate>Mon, 09 Mar 2026 12:00:00 GMT</pubDate>
<description>Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 being held virtually on March 10 -11, 2026. Mr. Feldschuh will deliver a 30-minute presentation on March 10 at 2:00 PM ET, and conduct virtual one-on-one meetings with institutional investors on March 11. Event:iAcces</description>
</item>
<item>
<title>Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-corporation-reports-2025-fiscal-year-results-operating-revenue-up-45percent-net-asset-value-rises-to-dollar907-per-share</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-corporation-reports-2025-fiscal-year-results-operating-revenue-up-45percent-net-asset-value-rises-to-dollar907-per-share</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE</description>
</item>
<item>
<title>Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-scales-outpatient-presence-launches-bva-diagnostic-program-in-tennessee</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-scales-outpatient-presence-launches-bva-diagnostic-program-in-tennessee</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>Expansion Leverages Daxor’s ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor</description>
</item>
<item>
<title>Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-corporation-announces-transition-securities-130000952</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-corporation-announces-transition-securities-130000952</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 (the Investment Company Act) to the Securities Exchange Act of 1934 (the “Exchange Act”), subject to its completion of required regulatory filings and approvals. This transition reflects the sustained rapid scaling and strategic matu</description>
</item>
<item>
<title>Daxor Corporation Announces $9 Million Registered Direct Offering</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-corporation-announces-9-million-130000203</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-corporation-announces-9-million-130000203</guid>
<pubDate>Fri, 23 Jan 2026 13:00:00 GMT</pubDate>
<description>OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the “Shares”) at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering t</description>
</item>
<item>
<title>Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-fuels-growth-three-facility-130000797</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-fuels-growth-three-facility-130000797</guid>
<pubDate>Tue, 25 Nov 2025 13:00:00 GMT</pubDate>
<description>Continued Integration of ezBVA Lab Service and On-Site Analyzer Deployment Signals Accelerating Market Traction Oak Ridge, TN, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its Blood Volume Analysis (BVA) platform into three new, prestigious facilities. This milestone demonstrates the accelerating market adoption of BVA's pivotal role in precision fluid management, leading to improved patien</description>
</item>
<item>
<title>Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-ceo-michael-feldschuh-engage-120000701</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-ceo-michael-feldschuh-engage-120000701</guid>
<pubDate>Tue, 21 Oct 2025 12:00:00 GMT</pubDate>
<description>Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will engage institutional investors at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025, at the Hard Rock Hotel in New York</description>
</item>
<item>
<title>Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-bva-technology-showcased-medaxiom-120000906</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-bva-technology-showcased-medaxiom-120000906</guid>
<pubDate>Wed, 15 Oct 2025 12:00:00 GMT</pubDate>
<description>OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall’25 Conference being held at the JW Marriott Austin, from Thursday, October 16 - Saturday, October 18 in Austin, TX. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting industry innovators and thought leaders fr</description>
</item>
<item>
<title>Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-unveils-fda-cleared-bva-120000062</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-unveils-fda-cleared-bva-120000062</guid>
<pubDate>Tue, 30 Sep 2025 12:00:00 GMT</pubDate>
<description>Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The company’s successful debut of its newly FDA-cleared, next-generati</description>
</item>
<item>
<title>Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-corporation-unveils-breakthrough-next-120000768</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-corporation-unveils-breakthrough-next-120000768</guid>
<pubDate>Tue, 23 Sep 2025 12:00:00 GMT</pubDate>
<description>Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement OAK RIDGE, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis, Minnesota, from September 26-29, 2025. The company will debut its newly FDA-cleared, next-generation blood volume analyzer (BVA), signaling a n</description>
</item>
<item>
<title>Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care</title>
<link>https://6ix.com/company/daxor-corporation/news/daxors-blood-volume-analysis-validated-120000090</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxors-blood-volume-analysis-validated-120000090</guid>
<pubDate>Thu, 04 Sep 2025 12:00:00 GMT</pubDate>
<description>Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today highlighted the significant findings of a new pilot study published in the Journal of Critical Care. Co-authored by leading intensive care expert Jan Bakker, M.D., Ph.D., this piv</description>
</item>
<item>
<title>Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-corporation-present-h-c-120000208</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-corporation-present-h-c-120000208</guid>
<pubDate>Wed, 03 Sep 2025 12:00:00 GMT</pubDate>
<description>Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference being held on September 8-10, 2025 in New York City at the Lotte New York Palace Hotel. The presentation will be available on-demand beginning Friday, September 5 at 7:00 a.m. ET. Investors who wish to listen to the Company’s</description>
</item>
<item>
<title>Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter</title>
<link>https://6ix.com/company/daxor-corporation/news/daxor-corporation-ceo-president-michael-120000221</link>
<guid isPermaLink="true">https://6ix.com/company/daxor-corporation/news/daxor-corporation-ceo-president-michael-120000221</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "Patience, persistence and perspiration make an unbeatable combination for success." – Napoleon Hill. This timeless wisdom resonates deeply with the journey we've undertaken at Daxor Corporation, and it per</description>
</item>
</channel>
</rss>